Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Thrombelastography and tromboelastometry in assessing coagulopathy in trauma

Pär I Johansson, Trine Stissing, Louise Bochsen and 1 more

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine · 2009 · Review

doi:10.1186/1757-7241-17-45

Abstract

Death due to trauma is the leading cause of lost life years worldwide, with haemorrhage being responsible for 30-40% of trauma mortality and accounting for almost 50% of the deaths the initial 24 h. On admission, 25-35% of trauma patients present with coagulopathy, which is associated with a several-fold increase in morbidity and mortality. The recent introduction of haemostatic control resuscitation along with emerging understanding of acute post-traumatic coagulability, are important means to improve therapy and outcome in exsanguinating trauma patients. This change in therapy has emphasized the urgent need for adequate haemostatic assays to monitor traumatic coagulopathy and guide therapy. Based on the cell-based model of haemostasis, there is emerging consensus that plasma-based routine coagulation tests (RCoT), like prothrombin time (PT) and activated partial thromboplastin time (APTT), are inappropriate for monitoring coagulopathy and guide therapy in trauma. The necessity to analyze whole blood to accurately identify relevant coagulopathies, has led to a revival of the interest in viscoelastic haemostatic assays (VHA) such as Thromboelastography (TEG) and Rotation Thromboelastometry (ROTEM). Clinical studies including about 5000 surgical and/or trauma patients have reported on the benefit of using the VHA as compared to plasma-based assays, to identify coagulopathy and guide therapy. This article reviews the basic principles of VHA, the correlation between the VHA whole blood clot formation in accordance with the cell-based model of haemostasis, the current use of VHA-guided therapy in trauma and massive transfusion (haemostatic control resuscitation), limitations of VHA and future perspectives of this assay in trauma.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

On admission, 25-35% of trauma patients present with coagulopathy, which is associated with a several-fold increase in morbidity and mortality. Although the management of traumatic coagulopathy differs worldwide, the recent introduction of haemostatic control resuscitation and the emerging understanding of acute post-traumatic coagulopathy, emphasize the urgent need for adequate haemostatic assays to guide therapy. Classically, coagulopathy is often monitored by plasma-based routine coagulation tests (RCoT) such as activated partial thromboplastin time (APTT) and prothrombin time (PT). These assays were developed half a century ago to monitor haemophilia and anticoagulation therapy, but have unfortunately never been validated for the prediction of haemorrhage in a clinical setting. It should be noted that although abnormal PT and APTT are highly correlated with mortality in trauma patients, the cause of death in these patients is not identified as excessive bleeding. This lack of correlation with clinically relevant coagulopathies can be explained by the fact that plasma-based assays reflect only the small amount of thrombin formed during initiation of coagulation. Consequently, recent reviews have concluded that the plasma-based assays are inappropriate for monitoring coagulopathy or guide transfusion therapy, calling for new tests to monitor these complex patients.

In 1994, the classical clotting cascade of haemostasis was challenged by the introduction of a cell-based model of haemostasis emphasizing the importance of tissue factor (TF) as the initiator of coagulation and the pivotal role of platelets for intact haemostasis. The poor correlation between RCoT and clinical bleeding in e.g. trauma and surgery is, hence, explained by this new understanding of haemostasis.

The necessity to analyze whole blood to accurately identify relevant coagulopathies, has led to a revival of the interest in viscoelastic point-of-care haemostatic assays (VHA) such as Thromboelastography (TEG®) and Rotation Thromboelastometry (ROTEM®).

The objective of this article is to review the basic principles of VHA, the correlation between the result of VHA and clot formation in accordance with the cell-based model of haemostasis, the current use of VHA-guided therapy in trauma and massive transfusion (haemostatic control resuscitation), limitations of VHA and future perspectives of application of this assay.

Basic principles of VHA

Thrombelastography was first described in 1948 by H. Hartert, as a method to assess the viscoelastic properties of coagulation in whole blood under low shear conditions. The VHA gives a graphic presentation of clot formation and subsequent lysis. Blood is incubated at 37°C in a heated cup. Within the cup is suspended a pin connected to a detector system (a torsion wire in TEG and an optical detector in ROTEM). The cup and pin are oscillated relative to each other through an angle of 4° 45'. The movement is initiated from either the cup (TEG) or the pin (ROTEM). As fibrin forms between the cup and pin, the transmitted rotation from the cup to pin (TEG) or the impedance of the rotation of the pin (ROTEM) are detected at the pin and a trace generated (Figure 1). The trace is divided into parts that each reflects different stages of the haemostatic process (clotting time, kinetics, strength and lysis, Figure 1) with slightly different nomenclature for TEG and ROTEM (Table 1). Examples of traces generated from normal as compared to different pathological states are shown in Figure 2.

VHA can either be performed bedside using native non-anticoagulated blood if the sample is analyzed within 5 min or it can be performed in a laboratory setting, where citrated blood samples are employed. The technical stability of the VHA analysis is demonstrated by day-to-day variation (CV%) of 5-15% for the different parameters.

Compared to RCoT, VHA has several advantages. First, the evaluation of the coagulation system in whole blood allows assessment of the combined influence of circulating plasmatic and cellular (platelets, RBC, leukocytes) elements on clot formation, including platelet function. Second, the end-point is clinically relevant, i.e. clotting in whole blood (fibrin formation, clot retraction and fibrinolysis, Figure 2). Third, the results are available within a short time frame making them relevant to clinical decision-making.

VHA and the cell-based model of haemostasis

According to the cell-based model, haemostasis is described in three phases: Initiation, amplification and propagation. During initiation, circulating activated coagulation factor (F) VII (FVIIa) forms a complex with exposed TF on injured endothelium, which in the amplification stage generates a small amount of thrombin that mainly activates the platelets. In the propagation phase the coagulation factors assemble on the activated platelets generating large amounts of thrombin ("thrombin burst"). The rate and peak of thrombin generation influences the clot structure and stability, by activating FXIII to FXIIIa, which cross links fibrinogen and further stabilizes the clot. Furthermore, thrombin activates TAFI to TAFIa which prevents lysis of the fibrin clot.

The three different phases of cell-based haemostasis resulting in clot formation are reflected by the VHA. The structural changes in the clot along the VHA trace was recently investigated by scanning electron microscopy demonstrating that the R (TEG)/CT (ROTEM) corresponds to the initiation phase whereas K (TEG)/CFT (ROTEM) reflects the amplification phase. Our group and others have demonstrated that the thrombin burst is reflected by the α-angle (TEG/ROTEM), and determines the clot strength and stability. The ability of VHA to reflect thrombin generation has profound clinical utility because coagulation factor deficiencies secondary to e.g. massive bleeding, dilution, consumption and thrombocytopenia/pathy result in impaired thrombin generation and impaired clot strength (MA (TEG), MCF (ROTEM)). The whole blood based VHA, therefore, reveals the contribution of all circulating plasmatic and cellular components, in their actual concentrations, to clot formation. Importantly, enhanced fibrinolysis contributes significantly to bleeding in trauma patients as well as patients undergoing cardiac and liver surgery and patients with obstetric complications, and this condition is readily identified by VHA (Ly (TEG), CL (ROTEM)). In addition, VHA in vitro studies have evaluated the effects of hypothermia, acidosis, different crystalloids and colloids, pro-haemostatic and anti-fibrinolytic drugs, with results being highly relevant for the clinical setting.

VHA in the surgical setting

In the last 25 years, more than 20 clinical studies reporting on the benefit of using VHA when compared to RCoT to identify coagulopathy and guide transfusion therapy have been published (Table 2). The studies include three randomized clinical trials and involve more than 4,500 patients undergoing major surgery. The majority of studies have been performed in patients undergoing liver or cardiac surgery, all reporting of the benefit of using VHA when compared to RCoT, evidenced by reductions in transfusion requirements and need for re-exploration and improved ability to predict the need for blood transfusion in patients with VHA-guided therapy. Importantly, no study have to date reported a benefit of employing plasma-based RCoT to predict bleeding or guide transfusion therapy, when compared to VHA, supporting the scientific rationale of whole blood viscoelastic assays in this setting.

Massive transfusion

Our group reported the effect on mortality of guiding transfusion therapy in massively bleeding patients (n = 832, 21% trauma patients) by VHA as compared to RCoT. Patients treated according to the VHA results received more FFP and more platelets and had significantly lower 30-day mortality as compared to controls (20% vs. 32%).

It is intriguing that the increased amount of plasma and platelets administered based on the VHA results are associated with improved survival, in alignment with retrospective findings from the trauma setting as well as the implementation of blind transfusion protocols.

VHA in trauma

A conserved physiologic haemostatic response, characterized by immediate activation of coagulation and fibrinolysis followed by subsequent fibrinolytic shutdown and later reactivation is often observed in trauma patients. Post-traumatic coagulopathy is classically described as dysfunction and/or consumption of coagulation factors and platelets due to dilution, hypothermia and acidosis i.e., "the bloody viscious cycle" and the ability of VHA to identify these conditions has been extensively reported. At present, 10 studies including more than 700 patients have evaluated VHA in trauma patients (Table 3).

Kaufmann et al. found that in 69 patients with blunt trauma, 65% displayed hypercoagulability upon arrival at the emergency department (ED) whereas only 10% were hypocoagulable. Interestingly, a hypocoagulable TEG was associated with increased ISS and only ISS and VHA, not RCoT, was predictive for early transfusion. Schreiber and colleagues also found that hypercoagulability, as evaluated by VHA, was frequent (62%) in trauma patients (n = 65) upon arrival at the ED, and that this correlated with increased thrombin-antithrombin (TAT) complex generation. APTT, PT and platelet count where within normal limits and could, hence, not identify a hypercoagulable state. Rugeri and colleagues investigated 88 trauma patients and compared their VHA results with that of healthy subjects. They found that trauma patients demonstrated evidence of hypocoagulability, and that this was restricted to those trauma patients also being coagulopathic with RCoT.

Recently, Carroll and colleagues addressed the acute post-traumatic coagulopathy, reported by Brohi et al., by VHA analyses of samples obtained at the scene of accident and upon arrival in the ED in 161 trauma patients. Interestingly, they found that that the clot forming parameters demonstrated hypocoagulability and correlated with fatality, whereas none of the RCoT demonstrated such a correlation. This indicates that VHA is more sensitive in reflecting clinically relevant coagulopathies than RCoT. This has important implications, since the VHA result is available within a short time frame as interventions aiming at normalising the VHA profile and hence the coagulopathy, can be instituted early during resuscitation. The VHA results of acute post-traumatic coagulopathy presented by Carroll et al. do not, however, corroborate the frequency of hyperfibrinolysis reported by Brohi et al.. Only three patients (2%) demonstrated evidence of increased fibrinolysis compared to the hyperfibrinolysis described in the cohort of Brohi, using D-dimer as a marker of fibrinolysis. Levrat and colleagues reported in a cohort of 89 trauma patients that 5 (6%) showed evidence of increased fibrinolysis and that this correlated with euglobuline lysis time. In both the study of Carroll et al. and Levrat et al., hyperfibrinolysis was identified in the most severely injured patients and was associated with increased mortality rate confirming that although rare, this is a very serious condition. A unique feature of VHA is its ability to identify patients with increased fibrinolysis. This enables initiation of specific anti-fibrinolytic therapy, which is associated with decreased blood loss and/or transfusion requirements in non-trauma settings. The role of this therapy in trauma patients is currently under clinical evaluation http://www.crash2.lshtm.ac.uk/.

In a retrospective review of 44 combat patients with penetrating trauma Plotkin et al. reported that VHA was a more accurate indicator of blood product requirements than PT, APTT, and INR. They suggested that VHA aided by platelet count and haematocrit should guide blood transfusion requirements. This is in alignment with Martini and colleagues who demonstrated that VHA was superior than PT, APTT, and Activated Clotting Time in detecting clinically relevant clotting abnormalities after hypothermia, haemorrhagic shock and resuscitation in pigs.

Recently Jaeger and colleagues reported of a modification of the VHA (TEG) where the activator kaolin was substituted with TF (RapidTEG). In patients sustaining major blunt trauma they investigated the time from ED arrival to the results of standard TEG, RapidTEG and RCoT were available. RapidTEG was available significantly faster (19.2 min vs. 29.9 min for kaolin TEG and 34.1 min for RCoT). On average the time until the results were available was reduced by approximately 50% for RapidTEG as compared to standard TEG, which may be of clinical relevance.

VHA limitations

Important limitations of the VHA exist and should be taken into consideration when interpreting the results of the analysis. Firstly, though it is possible to adjust the temperature at which the blood sample is analysed, VHA is routinely performed at 37°C and therefore the effect of hypothermia will not be recognised. Secondly, the coagulation activators employed results in thrombin formation, which masks the possible inhibition that antithrombotic agents such as aspirin, NSAID, clopidogrel and eptifibatide may have on the platelets ability to aggregate. Consequently, a normal VHA profile does not rule out clinically significant platelet inhibition. Thirdly, the endothelial contribution to haemostasis is not displayed in VHA and therefore, conditions affecting the endothelium such as von Willebrand disease (vWD, quantitative or qualitative defects in vWF and, hence inability of the platelets to adhere to the endothelium), cannot be investigated. If these causes of abnormal bleeding can be excluded, then a normal VHA trace along with clinically significant bleeding necessitating blood transfusion is suspect of a surgical cause. Thus, our group found 97% predictability by VHA in identifying a surgical cause of bleeding in postoperative non-cardiac patients with ongoing transfusion requirements.

VHA future perspectives in trauma

Recently, the concept of acute traumatic coagulopathy (ATC) was introduced by Brohi et al. based on the observations that coagulopathy, as evaluated by increased PT, APTT and D-dimer levels, was present in trauma patients already upon arrival to the hospital. ATC was independent of traditional causes of coagulopathy but occurred only in patients with evident hypoperfusion. When evaluating trauma patients upon arrival at ED with VHA characteristic profiles are found that are related to ISS and mortality. In patients with minor trauma/tissue injury a normal VHA trace is seen (Figure 2A) whereas in patients with moderate trauma (ISS between 10-20) hypercoagulability is seen (Figure 2B). In patients with severe injury (ISS 20-35), an increased frequency of hypocoagulability is seen (Figure 2C) whereas patients with massive tissue injury (ISS above 30) hyperfibrinolysis is seen (Figure 2D). The different VHA traces indicate that different treatment strategies may be appropriate and this warrants further investigation.

Conclusion

Death due to trauma is the leading cause of lost life years worldwide, with haemorrhage being responsible for 30-40% of trauma mortality and accounting for almost 50% of the deaths the initial 24 h. There is emerging consensus that plasma-based assays are inappropriate for monitoring coagulopathy and guide transfusion therapy in trauma, and the cell-based model of haemostasis provides a reliable explanation for this notion. Clinical studies including more than 5000 surgical and/or trauma patients have reported on the benefit of using VHA when compared to RCoT to identify coagulopathy and guide transfusion therapy. However, at present no VHA guided transfusion therapy has been prospectively and independently validated in trauma patients, which is highly warranted.

Competing interests

PJ has received unrestricted research grants from Haemoscope Corp. Niles IL, USA. The other authors declare that they have no competing interests'.

Authors' contributions

PJ, SO conducted the MEDLINE search for relevant publications related to VHA. PJ, SO, LB, TS conducted review of the searched publications and jointly decided which to be included in the review. PJ, SO wrote the first draft of the manuscript. SO designed the figures for the manuscript. PJO SO, LB, TS developed the tables. All authors read and approved the final manuscript.

References 83

  1. 1.

    Hess JR Brohi K Dutton RP Hauser CJ Holcomb JB Kluger Y Mackway-Jones K Parr MJ Rizoli SB Yukioka T Hoyt DB Bouillon B The coagulopathy of trauma: a review of mechanismsJ Trauma2008 65748754

    Not in our library10.1097/ta.0b013e3181877a9c

  2. 2.

    Brohi K Cohen MJ Davenport RA Acute coagulopathy of trauma: mechanism, identification and effectCurr Opin Crit Care2007 13680685

    Not in our library10.1097/mcc.0b013e3282f1e78f

  3. 3.

    Hoyt DB Dutton RP Hauser CJ Hess JR Holcomb JB Kluger Y Mackway-Jones K Parr MJ Rizoli SB Yukioka T Bouillon B Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practiceJ Trauma2008 65755764

    Not in our library10.1097/ta.0b013e318185fa9f

  4. 4.

    Malone DL Hess JR Fingerhut A Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocolJ Trauma2006 60S91S96

    Not in our library10.1097/01.ta.0000199549.80731.e6

  5. 5.

    Geeraedts LM Jr Kaasjager HA van Vugt AB Frolke JP Exsanguination in trauma: A review of diagnostics and treatment optionsInjury2009 401120

    Not in our library10.1016/j.injury.2008.10.007

  6. 6.

    Johansson PI Hansen MB Sorensen H Transfusion practice in massively bleeding patients: time for a change?Vox Sang2005 899296

    Not in our library10.1111/j.1423-0410.2005.00668.x

  7. 7.

    Holcomb JB Jenkins D Rhee P Johannigman J Mahoney P Mehta S Cox ED Gehrke MJ Beilman GJ Schreiber M Flaherty SF Grathwohl KW Spinella PC Perkins JG Beekley AC McMullin NR Park MS Gonzalez EA Wade CE Dubick MA Schwab CW Moore FA Champion HR Hoyt DB Hess JR Damage control resuscitation: directly addressing the early coagulopathy of traumaJ Trauma2007 62307310

    Not in our library10.1097/ta.0b013e3180324124

  8. 8.

    Brohi K Cohen MJ Ganter MT Matthay MA Mackersie RC Pittet JF Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?Ann Surg2007 245812818

    Not in our library10.1097/01.sla.0000256862.79374.31

  9. 9.

    Brohi K Cohen MJ Ganter MT Schultz MJ Levi M Mackersie RC Pittet JF Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysisJ Trauma2008 6412111217

    Not in our library10.1097/ta.0b013e318169cd3c

  10. 10.

    Shapiro S Sherwin B Gordimer H Postoperative thromboembolization: The platelet count and the prothrombin time after surgical operations: A simpe method for detecting reductions and elevations of the prothrombin concentration (or activity) of the blood plasmaAnn Surg1942 116175183

    Not in our library10.1097/00000658-194208000-00002

  11. 11.

    Proctor RR Rapaport SI The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficienciesAm J Clin Pathol1961 36212219

    Not in our library10.1093/ajcp/36.3.212

  12. 12.

    Aoki N Wall MJ Demsar J Zupan B Granchi T Schreiber MA Holcomb JB Byrne M Liscum KR Goodwin G Beck JR Mattox KL Predictive model for survival at the conclusion of a damage control laparotomyAm J Surg2000 180540544

    Not in our library10.1016/s0002-9610(00)00497-9

  13. 13.

    Brohi K Singh J Heron M Coats T Acute traumatic coagulopathyJ Trauma2003 5411271130

    Not in our library10.1097/01.ta.0000069184.82147.06

  14. 14.

    MacLeod JB Lynn M McKenney MG Cohn SM Murtha M Early coagulopathy predicts mortality in traumaJ Trauma2003 553944

    Not in our library10.1097/01.ta.0000075338.21177.ef

  15. 15.

    Segal JB Dzik WH Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based reviewTransfusion2005 4514131425

    Not in our library10.1111/j.1537-2995.2005.00546.x

  16. 16.

    Levi M Opal SM Coagulation abnormalities in critically ill patientsCrit Care2006 10222

    Not in our library10.1186/cc4975

  17. 17.

    Fries D Innerhofer P Schobersberger W Time for changing coagulation management in trauma-related massive bleedingCurr Opin Anaesthesiol2009 22267274

    Not in our library10.1097/aco.0b013e32832678d9

  18. 18.

    Bartal C Yitzhak A The role of thromboelastometry and recombinant factor VIIa in traumaCurr Opin Anaesthesiol2009 22281288

    Not in our library10.1097/aco.0b013e328325a6be

  19. 19.

    Macfarlane RG An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifierNature1964 202498499

    Not in our library10.1038/202498a0

  20. 20.

    Davie EW Ratmoff OD Waterfall sequence for intrinsic blood clottingScience1964 14513101312

    Not in our library10.1126/science.145.3638.1310

  21. 21.

    Monroe DM Roberts HR Hoffman M Platelet procoagulant complex assembly in a tissue factor-initiated systemBr J Haematol1994 88364371

    Not in our library10.1111/j.1365-2141.1994.tb05032.x

  22. 22.

    Martini WZ Cortez DS Dubick MA Park MS Holcomb JB Thrombelastography is Better Than PT, aPTT, and Activated Clotting Time in Detecting Clinically Relevant Clotting Abnormalities After Hypothermia, Hemorrhagic Shock and Resuscitation in PigsJ Trauma2008 65535543

    Not in our library10.1097/ta.0b013e31818379a6

  23. 23.

    Plotkin AJ Wade CE Jenkins DH Smith KA Noe JC Park MS Perkins JG Holcomb JB A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuriesJ Trauma2008 64S64S68

    Not in our library10.1097/ta.0b013e318160772d

  24. 24.

    Gravlee GP Arora S Lavender SW Mills SA Hudspeth AS Cordell AR James RL Brockschmidt JK Stuart JJ Predictive value of blood clotting tests in cardiac surgical patientsAnn Thorac Surg1994 58216221

    Not in our library10.1016/0003-4975(94)91103-7

  25. 25.

    Murray D Pennell B Olson J Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleedingTransfusion1999 395662

    Not in our library10.1046/j.1537-2995.1999.39199116895.x

  26. 26.

    Hartert H Blutgerinnungsstudien mit der thrombelastographie, einem neuen untersuchungsverfahrenKlin Wochenschr1948 26577583

    Not in our library10.1007/bf01697545

  27. 27.

    Salooja N Perry DJ ThrombelastographyBlood Coagul Fibrinolysis2001 12327337

    Not in our library10.1097/00001721-200107000-00001

  28. 28.

    Luddington RJ Thrombelastography/thromboelastometryClin Lab Haematol2005 278190

    Not in our library10.1111/j.1365-2257.2005.00681.x

  29. 29.

    Chandler WL The thromboelastography and the thromboelastograph techniqueSemin Thromb Hemost1995 21Suppl 416

    Not in our library

  30. 30.

    Di Benedetto P Baciarello M Cabetti L Martucci M Chiaschi A Bertini L Thrombelastography. Present and future perspectives in clinical practiceMinerva Anestesiol2003 69501515

    Not in our library

  31. 31.

    Ganter MT Hofer CK Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devicesAnesth Analg2008 10613661375

    Not in our library10.1213/ane.0b013e318168b367

  32. 32.

    Johansson PI Bochsen L Andersen S Viuff D Investigation of the effect of kaolin and tissue factor-activated citrated whole blood, on clot forming variables, as evaluated by thromboelastographyTransfusion2008 4823772383

    Not in our library10.1111/j.1537-2995.2008.01846.x

  33. 33.

    Jennings I Kitchen DP Woods TA Kitchen S Walker ID Emerging technologies and quality assurance: the United Kingdom National External Quality Assessment Scheme perspectiveSemin Thromb Hemost2007 33243249

    Not in our library10.1055/s-2007-971810

  34. 34.

    Roberts HR Monroe DM Escobar MA Current concepts of hemostasis: implications for therapyAnesthesiology2004 100722730

    Not in our library10.1097/00000542-200403000-00036

  35. 35.

    Monroe DM Hoffman M Roberts HR Platelets and thrombin generationArterioscler Thromb Vasc Biol2002 2213811389

    Not in our library10.1161/01.atv.0000031340.68494.34

  36. 36.

    Hoffman MM Monroe DM Rethinking the coagulation cascadeCurr Hematol Rep2005 4391396

    Not in our library

  37. 37.

    Allen GA Wolberg AS Oliver JA Hoffman M Roberts HR Monroe DM Impact of procoagulant concentration on rate, peak and total thrombin generation in a model systemJ Thromb Haemost2004 2402413

    Not in our library10.1111/j.1538-7933.2003.00617.x

  38. 38.

    Lorand L Factor XIII: structure, activation, and interactions with fibrinogen and fibrinAnn N Y Acad Sci2001 936291311

    Not in our library10.1111/j.1749-6632.2001.tb03516.x

  39. 39.

    Bouma BN Meijers JC Role of blood coagulation factor XI in downregulation of fibrinolysisCurr Opin Hematol2000 7266272

    Not in our library10.1097/00062752-200009000-00002

  40. 40.

    Kawasaki J Katori N Kodaka M Miyao H Tanaka KA Electron microscopic evaluations of clot morphology during thrombelastographyAnesth Analg2004 9914401444

    Not in our library10.1213/01.ane.0000134805.30532.59

  41. 41.

    Johansson PI Svendsen MS Salado J Bochsen L Kristensen AT Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 daysVox Sang2008 94113118

    Not in our library10.1111/j.1423-0410.2007.01011.x

  42. 42.

    Rivard GE Brummel-Ziedins KE Mann KG Fan L Hofer A Cohen E Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastographyJ Thromb Haemost2005 320392043

    Not in our library10.1111/j.1538-7836.2005.01513.x

  43. 43.

    Sorensen B Ingerslev J Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastographyHaemophilia2005 11Suppl 116

    Not in our library10.1111/j.1365-2516.2005.01156.x

  44. 44.

    Chakroun T Gerotziafas GT Seghatchian J Samama MM Hatmi M Elalamy I The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profileThromb Haemost2006 95822828

    Not in our library

  45. 45.

    Nielsen VG Cohen BM Cohen E Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activationBlood Coagul Fibrinolysis2006 177581

    Not in our library10.1097/01.mbc.0000198047.35010.77

  46. 46.

    Kheirabadi BS Crissey JM Deguzman R Holcomb JB In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin timeJ Trauma2007 6213521359

    Not in our library10.1097/ta.0b013e318047b805

  47. 47.

    Viuff D Lauritzen B Pusateri AE Andersen S Rojkjaer R Johansson PI Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven(R))Br J Anaesth2008 101324331

    Not in our library10.1093/bja/aen175

  48. 48.

    Jones SB Whitten CW Despotis GJ Monk TG The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markersAnesth Analg2003 963638

    Not in our library10.1097/00000539-200302000-00012

  49. 49.

    Hendriks HG Meijer K de Wolf JT Porte RJ Klompmaker IJ Lip H Slooff MJ van der Meer MJ Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantationBlood Coagul Fibrinolysis2002 13309313

    Not in our library10.1097/00001721-200206000-00006

  50. 50.

    Nielsen VG Cankovic L Steenwyk BL Epsilon-aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered?Blood Coagul Fibrinolysis2007 183539

    Not in our library10.1097/mbc.0b013e328010a359

  51. 51.

    Kang YG Martin DJ Marquez J Lewis JH Bontempo FA Shaw BW Jr Starzl TE Winter PM Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantationAnesth Analg1985 64888896

    Not in our library10.1213/00000539-198509000-00008

  52. 52.

    McNicol PL Liu G Harley ID McCall PR Przybylowski GM Bowkett J Angus PW Hardy KJ Jones RM Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastographyAnaesth Intensive Care1994 22659665

    Not in our library10.1177/0310057x9402200603

  53. 53.

    Spiess BD Gillies BS Chandler W Verrier E Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patientsJ Cardiothorac Vasc Anesth1995 9168173

    Not in our library10.1016/s1053-0770(05)80189-2

  54. 54.

    Shore-Lesserson L Manspeizer HE DePerio M Francis S Vela-Cantos F Ergin MA Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgeryAnesth Analg1999 88312319

    Not in our library10.1097/00000539-199902000-00016

  55. 55.

    Manikappa S Mehta Y Juneja R Trehan N Changes in transfusion therapy guided by thromboelastograph in cardiac surgeryAnn Card Anaesth2001 42127

    Not in our library

  56. 56.

    Anderson L Quasim I Soutar R Steven M Macfie A Korte W An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unitTransfus Med2006 163139

    Not in our library10.1111/j.1365-3148.2006.00645.x

  57. 57.

    Welsby IJ Jiao K Ortel TL Brudney CS Roche AM Bennett-Guerrero E Gan TJ The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgeryJ Cardiothorac Vasc Anesth2006 20531535

    Not in our library10.1053/j.jvca.2005.04.013

  58. 58.
    Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study · 2009
    No notice
  59. 59.

    Holcomb JB Wade CE Michalek JE Chisholm GB Zarzabal LA Schreiber MA Gonzalez EA Pomper GJ Perkins JG Spinella PC Williams KL Park MS Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patientsAnn Surg2008 248447458

    Not in our library10.1097/sla.0b013e318185a9ad

  60. 60.

    Cotton BA Gunter OL Isbell J Au BK Robertson AM Morris JA Jr St Jacques P Young PP Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilizationJ Trauma2008 6411771182

    Not in our library10.1097/ta.0b013e31816c5c80

  61. 61.

    Gando S Disseminated intravascular coagulation in trauma patientsSemin Thromb Hemost2001 27585592

    Not in our library10.1055/s-2001-18864

  62. 62.

    Kaufmann CR Dwyer KM Crews JD Dols SJ Trask AL Usefulness of thrombelastography in assessment of trauma patient coagulationJ Trauma1997 42716720

    Not in our library10.1097/00005373-199704000-00023

  63. 63.

    Schreiber MA Differding J Thorborg P Mayberry JC Mullins RJ Hypercoagulability is most prevalent early after injury and in female patientsJ Trauma2005 58475480

    Not in our library10.1097/01.ta.0000153938.77777.26

  64. 64.

    Rugeri L Levrat A David JS Delecroix E Floccard B Gros A Allaouchiche B Negrier C Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastographyJ Thromb Haemost2007 5289295

    Not in our library10.1111/j.1538-7836.2007.02319.x

  65. 65.

    Carroll RC Craft RM Langdon RJ Clanton CR Snider CC Wellons DD Dakin PA Lawson CM Enderson BL Kurek SJ Early evaluation of acute traumatic coagulopathy by thrombelastographyTransl Res2009 1543439

    Not in our library10.1016/j.trsl.2009.04.001

  66. 66.

    Levrat A Gros A Rugeri L Inaba K Floccard B Negrier C David JS Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patientsBr J Anaesth2008 100792797

    Not in our library10.1093/bja/aen083

  67. 67.

    Jeger V Zimmermann H Exadaktylos AK Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries?J Trauma2009 6612531257

    Not in our library10.1097/ta.0b013e31819d3caf

  68. 68.

    Johansson PI Treatment of massively bleeding patients: introducing real-time monitoring, transfusion packages and thrombelastography (TEGR)ISBT Science Series2007 2159167

    Not in our library10.1111/j.1751-2824.2007.00084.x

  69. 69.

    Johansson PI Bochsen L Stensballe J Secher NH Transfusion packages for massively bleeding patients: The effect on clot formation and stability as evaluated by Thrombelastograph (TEG)Transfus Apher Sci2008 3938

    Not in our library10.1016/j.transci.2008.05.012

  70. 70.

    Avikainen V Coagulation disorders in severely and critically injured patientsAnn Chir Gynaecol1977 66269277

    Not in our library

  71. 71.

    Henry DA Carless PA Moxey AJ O'Connell D Stokes BJ McClelland B Laupacis A Fergusson D Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusionCochrane Database Syst Rev2007 CD001886

    Not in our library10.1002/14651858.cd001886.pub2

  72. 72.

    Coats T Roberts I Shakur H Antifibrinolytic drugs for acute traumatic injuryCochrane Database Syst Rev2004 CD004896

    Not in our library10.1002/14651858.cd004896.pub2

  73. 73.

    Douning LK Ramsay MA Swygert TH Hicks KN Hein HA Gunning TC Suit CT Temperature corrected thrombelastography in hypothermic patientsAnesth Analg1995 81608611

    Not in our library10.1097/00000539-199509000-00033

  74. 74.

    Kettner SC Sitzwohl C Zimpfer M Kozek SA Holzer A Spiss CK Illievich UM The effect of graded hypothermia (36 degrees C-32 degrees C) on hemostasis in anesthetized patients without surgical traumaAnesth Analg2003 9617726table

    Not in our library10.1213/01.ane.0000062520.65192.c9

  75. 75.

    Swallow RA Agarwala RA Dawkins KD Curzen NP Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?Platelets2006 17385392

    Not in our library10.1080/09537100600757521

  76. 76.

    Kang Y Thromboelastography in liver transplantationSemin Thromb Hemost1995 213444

    Not in our library

  77. 77.

    Harding SA Mallett SV Peachey TD Cox DJ Use of heparinase modified thrombelastography in liver transplantationBr J Anaesth1997 78175179

    Not in our library10.1093/bja/78.2.175

  78. 78.

    Chau TN Chan YW Patch D Tokunaga S Greenslade L Burroughs AK Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleedingGut1998 43267271

    Not in our library10.1136/gut.43.2.267

  79. 79.

    Tuman KJ Spiess BD McCarthy RJ Ivankovich AD Effects of progressive blood loss on coagulation as measured by thrombelastographyAnesth Analg1987 66856863

    Not in our library10.1213/00000539-198709000-00009

  80. 80.

    Spiess BD Tuman KJ McCarthy RJ DeLaria GA Schillo R Ivankovich AD Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathiesJ Clin Monit1987 32530

    Not in our library10.1007/bf00770880

  81. 81.

    Tuman KJ Spiess BD McCarthy RJ Ivankovich AD Comparison of viscoelastic measures of coagulation after cardiopulmonary bypassAnesth Analg1989 696975

    Not in our library10.1213/00000539-198907000-00013

  82. 82.

    Essell JH Martin TJ Salinas J Thompson JM Smith VC Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypassJ Cardiothorac Vasc Anesth1993 7410415

    Not in our library10.1016/1053-0770(93)90161-d

  83. 83.

    Tuman KJ McCarthy RJ Djuric M Rizzo V Ivankovich AD Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assayJ Cardiothorac Vasc Anesth1994 8144149

    Not in our library10.1016/1053-0770(94)90052-3

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.